Key points are not available for this paper at this time.
Background and objective: This study explores the associations of sarcopenia, obesity, and their coexistence (sarcopenic obesity) with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS). Methods: ), and sarcopenic obesity. LUTS/BPH was assessed according to each patient's medical history. Logistic regression was used to evaluate the association of obesity, sarcopenia, and sarcopenic obesity with BPH/LUTS. Interaction effects were further assessed to investigate the combined impact of sarcopenia and obesity. Key findings and limitations: = 0.9). Sensitivity analyses confirmed these findings. The interaction between sarcopenia and obesity was significant, with 40% (95% CI 13-56%) of the risk attributed to their combined effect. Conclusions and clinical implications: Sarcopenic obesity was independently associated with higher risk of BPH/LUTS among older men in our cohort. Our study highlights the synergistic interaction between sarcopenia and obesity, and suggests a need for comprehensive management of both conditions to reduce the risk of BPH/LUTS. Patient summary: We looked at associations between a condition called sarcopenic obesity (obesity and a loss of muscle mass) and benign enlargement of the prostate gland causing urinary problems (called BPH/LUTS for short). We found that sarcopenic obesity is associated with a higher risk of BPH/LUTS in older men.
Zhou et al. (2025) studied this question.